This randomised, double-blind study was designed to investigate the efficacy of a once-daily (OD) combination of the AT 1 receptor blocker, eprosartan 600 mg, and the thiazide diuretic, hydrochlorothiazide (HCTZ) 12.5 mg, in patients with mild to moderate hypertension (sitting diastolic blood pressure (sitDBP) у98 mm Hg and р114 mm Hg) not adequately controlled with eprosartan 600 mg OD. A total of 494 patients entered the open-label monotherapy run-in phase, which consisted of eprosartan 600 mg OD for 3 weeks. Patients who responded to monotherapy were not eligible to enter the randomised phase of the study and were withdrawn. The remaining 309 patients were then randomised to either eprosartan 600 mg plus HCTZ 12.5 mg OD or to continue on eprosartan 600 mg OD. In the eprosartan plus HCTZ combination group, both sitDBP and sitting systolic blood pressure (sitSBP) were significantly
Introduction
The renin-angiotensin-aldosterone system (RAAS) plays an important role in the regulation of several aspects of cardiovascular and renal function, including blood pressure. Angiotensin-II (A-II), the primary effector hormone, is produced by the action of angiotensin-converting enzyme (ACE) on angiotensin-I. By binding to the angiotensin-II receptor (subtype AT 1 ), A-II initiates several actions including promotion of sodium retention, vasoconstriction and increased blood volume. Vasoconstriction leads to increased peripheral resistance and, therefore, increases in blood pressure.
For nearly 20 years, ACE inhibitors have been used to lower blood pressure and to reduce structural vascular changes. 1 However, as ACE is identical to kinase II and is relatively non-specific, ACE inhibitors can also block the breakdown of peptides, such as bradykinin and substance P. 2 This results in the occurrence of side effects such as dry cough and other upper respiratory tract symptoms. It is also known that A-II can be formed by other enzymes, such as chymase. 3 Therefore, the use of angiotensin receptor blockers may be a more effective mechanism of inhibition of the RAAS and may avoid some of the side effects that occur with ACE inhibitors.
Eprosartan is an orally active, highly selective, non-peptide, non-biphenyl, non-tetrazole angiotensin receptor blocker that has been shown in clinical studies to be effective in reducing both systolic and diastolic blood pressure in patients with mild, moderate 4, 5 and severe hypertension. 6 It also has a good safety and tolerability profile. 7 The conventional approach to the management of patients with uncomplicated hypertension is treatment with a single antihypertensive agent, titrating to the maximum recommended dose to achieve blood pressure control. Monotherapy with eprosartan 600 mg once-daily (OD) produces an adequate response in up to 40-50% of patients with essential
Journal of Human Hypertension hypertension. 4, 8 The recommended standard dose for eprosartan is 600 mg OD, but this can be increased by dose titration to 800 mg OD if needed. However, the non-responsive patient may need to be prescribed an additional drug, usually from a different class, such as a diuretic. The addition of a diuretic, such as hydrochlorothiazide (HCTZ), can result in an increase in response rate to about 80-85% in patients insufficiently responsive to monotherapy. 9, 10 Antihypertensive agents that inhibit the RAAS are known to be more effective in some patients than others. Thiazide diuretics act as vasodilators by increasing the excretion of water and solutes, mainly NaCl. They inhibit the RAAS by producing volume depletion and when administered with an angiotensin receptor blocker, result in greater antihypertensive efficacy than either agent alone. 11, 12 In patients in whom blood pressure is not controlled with eprosartan monotherapy, further reductions in blood pressure can therefore be achieved using eprosartan in combination with a diuretic, such as HCTZ. 13 Long-term safety studies 14, 15 have shown that over a 2-year period, once-daily eprosartan is well tolerated over the dose range 400-800 mg in patients with mild to moderate hypertension. For patients whose blood pressure was not adequately controlled by 800 mg eprosartan, HCTZ at doses up to 25 mg was combined with eprosartan. Thus, 35% of patients who were uptitrated to eprosartan 800 mg plus HCTZ 25 mg achieved normalisation. The increased benefit of eprosartan and HCTZ combination therapy (eprosartan + HCTZ) may be a result of a synergistic effect on the RAAS, with eprosartan exerting its effect by blocking the AT 1 receptor and HCTZ exerting its effect on the kidney, leading to volume depletion and thus RAAS inhibition.
The primary objective of this study was to evaluate the efficacy of a once-daily combination of eprosartan 600 mg plus HCTZ 12.5 mg in patients with essential hypertension (average sitting diastolic blood pressure (sitDBP) у98 mm Hg and р114 mm Hg) not adequately controlled with eprosartan 600 mg OD. In addition, the tolerability of a oncedaily combination of eprosartan and HCTZ was assessed with regard to adverse events, laboratory abnormalities and electrocardiograms (ECGs).
Patients and methods

Study design
This was a European multicentre, prospective, randomised, double-blind, parallel group study which was performed in 29 centres in France (n = 17), Belgium (n = 6) and the Republic of Ireland (n = 6). The study consisted of four phases: screening (at least 1 week); open-label monotherapy run-in of 600 mg eprosartan OD (3 weeks); double-blind treatment (8 weeks); and follow-up (1-4 weeks) . Following the open-label monotherapy run in, patients who responded to treatment with eprosartan 600 mg OD were defined as monotherapy responders and so were not randomised to the second part of the study. Monotherapy responders were classified as those patients whose sitDBP had fallen below 90 mm Hg or was in the range 90-100 mm Hg having decreased by at least 10 mm Hg. Patients whose diastolic blood pressure was not successfully controlled or lowered by at least 10 mm Hg and below 100 mm Hg with monotherapy entered the double-blind treatment phase and were randomised to receive either eprosartan 600 mg plus HCTZ 12.5 mg OD or to continue on eprosartan 600 mg OD. Patients then remained on their medication for the 8 weeks of the double-blind treatment period. A follow-up visit was carried out for all patients 1-4 weeks after the last dose of study medication.
Patient population
This study included men and women who were at least 18 years of age and who had recently been diagnosed with essential hypertension or had previously had antihypertensive therapy that could safely be withdrawn for the duration of the screening period (all antihypertensive medication was withdrawn at least 1 week before the screening visit). All subjects had a diagnosis of mild to moderate hypertension with an average sitDBP within the range у98 mm Hg and р114 mm Hg at screening.
Patients were excluded if they had renal or hepatic disease; severe hypertension or other forms of concurrent severe disease; diabetes mellitus that was unstable; or if they had received concomitant treatment with drugs known to affect blood pressure, sympathomimetic amines, non-steroidal antiinflammatory drugs, monoamine oxidase inhibitors, tricyclic antidepressants, or phenothiazine derivatives. Patients who were sensitive to eprosartan, HCTZ or other drugs in their respective classes, or patients who had received randomised active eprosartan medication in a previous trial of eprosartan, were excluded. Women of child-bearing age were excluded if they did not use hormonal, barrier or intrauterine contraception, as were those who were pregnant or lactating.
Patients could be withdrawn from the study prior to completion for the following reasons: adverse events judged by the investigator to warrant withdrawal; insufficient therapeutic effect as defined by mean sitDBP Ͼ120 mm Hg; mean sitDBP between 115 mm Hg and 120 mm Hg that remained for 3 days; mean sitting systolic blood pressure (sitSBP) Ͼ200 mm Hg at two consecutive visits; blood pressure increase to a medically unacceptable level; or a protocol violation, such as non-compliance.
The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The protocol and statement of informed consent were approved by ethics committees.
Efficacy assessments
Baseline measurements for vital signs and severity of hypertension were measured at the end of the eprosartan monotherapy run-in period. The primary objective of the study was to evaluate the efficacy of a once-daily combination of eprosartan 600 mg plus HCTZ 12.5 mg in patients with essential hypertension (average sitDBP у98 mm Hg and р114 mm Hg) not adequately controlled with eprosartan 600 mg once-daily. Vital signs and blood pressure measurements were assessed at weeks 2, 4, 8 and at followup (1-4 weeks).
The primary end-point was measurement of trough sitDBP at study end-point, which was defined as the last measurement taken for a randomised patient who had taken at least one dose of double-blind treatment. The secondary end-points were measurement of trough sitSBP and heart rate (HR); the proportion of patients whose sitDBP had normalised (defined as a sitDBP Ͻ90 mm Hg); and the proportion of responders (ie, the percentage of patients whose sitDBP had either normalised or whose sitDBP was р100 mm Hg and decreased from baseline by at least 10 mm Hg) at study end-point.
Measurement of sitDBP and sitSBP were assessed as follows: after the patient sat quietly for at least 5 min, blood pressure and heart rate were measured three times at approximately 2-min intervals. The three measurements were recorded and averaged to obtain the mean values for sitDBP, sitSBP and HR.
Tolerability assessments
Tolerability assessments were performed at the screening visit, baseline, at the end of the doubleblind treatment period and at follow-up, and were based on the incidence of adverse events and on vital signs data, laboratory abnormalities and ECG values.
An adverse event (AE) was classified as an untoward event recorded either voluntarily by the patient in response to a non-leading question (ie, investigators asked patients whether they felt differently in any way since starting the new treatment) or following a clinical observation. Adverse events assessed by the investigator were defined according to their severity, relationship to study medication, corrective therapy, and outcome status.
Statistical analyses
All patients who received at least one dose of randomised study medication and had an on-therapy vital sign measurement were included in the intentto-treat analysis. For efficacy evaluations the mean change from baseline in trough sitDBP, mean change from baseline in trough sitSBP, the proportion of patients whose blood pressure normalised (sitDBP Ͻ90 mm Hg), and the proportion of responders at study end-point were determined.
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The following subgroups were investigated for their effect on the mean change from baseline in trough sitDBP at study end-point: age (Ͻ65 years, у65 years), gender, race, prior use of antihypertensives, and severity of hypertension (sitDBP Ͻ100 mm Hg, у100 mm Hg) at baseline. For each of the groups, this was done by including the subgroup variable together with treatment, centre, and treatment-by-subgroup interaction in an analysis of variance.
Continuous variables were assessed by analysis of variance, which included terms for centre, treatment and centre-by-treatment interaction. For response and normalisation rates at study end-point, the difference between the two treatment groups was assessed using the Cochran-Mantel-Haenszel statistic controlling for centres. Relative risks for normalisation and response rates were reported together with 95% confidence intervals (CI) and range of intervals.
All patients who received at least one dose of study medication were assessed for tolerability. Evaluation of tolerability data was based on comparisons of patient experience by treatment group and by subgroup within the treatment groups. Clinical interpretation of tolerability was based on reviews of standard displays of adverse event according to treatment and time of onset.
Results
Study population
A total of 518 patients were screened and 494 patients entered the eprosartan 600 mg monotherapy run-in period. Among the 185 patients who were not randomised, 125 patients responded to eprosartan monotherapy and so did not qualify for randomisation. Of the other 60 patients who were not randomised, 35 patients did not proceed at the request of the sponsor (due to over-enrolment of the study), 10 patients withdrew due to adverse events, four withdrew due to lack of efficacy and 11 withdrew due to a protocol violation (including noncompliance). Three hundred and nine patients were randomised to double-blind medication with 157 patients in the eprosartan monotherapy group and 152 patients in the combination group.
The baseline characteristics of patients receiving randomised treatment including severity of hypertension (Ͻ100 mm Hg, у100 mm Hg), prior use of antihypertensives, and mean sitDBP, sitSBP and sitHR were similar between groups (Table 1 ). In addition, the treatment groups had similar demographic and clinical characteristics with respect to race, weight and height. There was a higher proportion of females (65%) in the monotherapy run-in group compared with the approximately equal distribution seen in the randomised group. The majority of patients randomised to double-blind treatment were Caucasian (97.4%), with a mean age of 56 years, and 52.4% were male (Table 1) . Two hundred and ninety patients went on to complete the study. Patients were considered to have reached the study end-point if they had completed the 8 weeks of double-blind treatment. Four patients were randomised to double-blind treatment but not included in the efficacy analysis because they were withdrawn before an on-therapy assessment was performed. Therefore, 305 patients were included in the efficacy analysis, with 156 patients in the eprosartan 600 mg monotherapy group and 149 patients in the eprosartan 600 mg plus HCTZ 12.5 mg combination group.
Eight patients were inadvertently randomised to double-blind treatment after they had responded to monotherapy treatment. Three of these patients were randomised to the monotherapy group and five to the combination group. In six of the seven patients who completed the study, sitDBP had reduced further at study end-point compared with baseline.
Efficacy results
The primary end-point was the mean (± s.e.m.) change in trough sitDBP from baseline to study endpoint (Figure 1) . Sitting DBP at baseline was similar for both treatment groups (99.0 ± 0.4 mm Hg for the monotherapy group and 99.8 ± 0.4 mm Hg for the combination group). In the combination group, sitDBP was reduced by 10.7 ± 0.7 mm Hg (95% CI −9.3, −6.6) compared with a reduction of 7.9 ± 0.7 mm Hg (95% CI −12.1, −9.3) in the monotherapy group. The difference between the groups −2.8 mm Hg (95% CI −4.4, −1.1) was statistically significant (P = 0.001).
The mean trough sitDBP at baseline and study end-point, and change from baseline at study weeks 2, 4, 8 and study end-point were also analysed. At each time point (2, 4 and 8 weeks) both treatments produced a decrease in the mean trough sitDBP compared with baseline (Figure 2) , and at all time points the mean changes in sitDBP were numerically greater for the combination group compared with the eprosartan group. At weeks 2, 4 and 8 the changes in sitDBP from baseline were −6.3 mm Hg, −7.8 mm Hg and −9.1 mm Hg for the monotherapy group and −9.3 mm Hg, −10.6 mm Hg and −11.3 mm Hg for the combination group, respectively. Baseline measurements of sitSBP were similar for both treatment groups (156.0 ± 1.1 mm Hg for the eprosartan group and 155.1 ± 1.2 mm Hg for the Journal of Human Hypertension combination group). Baseline sitSBP was reduced at study end-point by 9.2 ± 1.1 mm Hg (95% CI −11.4, −7.0) in the combination group and by 5.8 ± 1.1 mm Hg (95% CI −7.9, −3.7) in the monotherapy group. The change in sitSBP between the two treatment groups was 3.4 mm Hg (95% CI −5.9, −0.8) in favour of the combination group compared with the monotherapy group (P = 0.01). At each time point (2, 4 and 8 weeks) the combination group produced a larger reduction in sitSBP, with at least a 2.7 mm Hg greater reduction numerically, relative to the monotherapy group at all times (Figure 3) . At weeks 2, 4 and 8 the changes in sitSBP from baseline were −7.2 mm Hg, −9.2 mm Hg and −9.5 mm Hg for the monotherapy group and −10.5 mm Hg, −12.3 mm Hg and −12.2 mm Hg for the combination group, respectively.
Patients with sitDBP below 90 mm Hg at the study end-point were considered to have normalised diastolic blood pressure. The mean sitDBP at study endpoint were 90.5 mm Hg and 88.3 mm Hg for the monotherapy and combination groups, respectively. At study end-point, normalisation rates for the monotherapy group and the combination group were 48.7% (76/156) and 59.1% (88/149), respectively, although this difference was not statistically significant (P = 0.10).
The response rate (ie, the percentage of patients whose sitDBP was Ͻ90 mm Hg at study end-point or whose sitDBP was in the range 90-100 mm Hg Figure 3 Least squares mean ± s.e.m. changes from baseline for sitting systolic blood pressure (sitSBP) at weeks 2, 4 and 8 in patients randomised to receive eprosartan 600 mg or eprosartan 600 mg plus HCTZ 12.5 mg.
and had decreased from baseline by at least 10 mm Hg) was statistically higher in the combination group (73.2%) when compared with the monotherapy group (57.1%; P = 0.004).
Subgroup analyses revealed a significant interaction (P = 0.07) between the treatment effect and age. In the age group of Ͻ65 years, there was a difference in the mean change from baseline for sitDBP of 4 mm Hg between the combination group (−11.6 mm Hg) vs the monotherapy group (−7.6 mm Hg), whereas in the age group of patients у65 years of age this difference was no longer apparent with a difference of 0.2 mm Hg (−11.4 mm Hg in combination group and −11.2 mm Hg in monotherapy group). The blood pressure lowering effect appeared to be similar for the two age groups for the combination group, whereas a larger reduction in sitDBP was observed among those patients у65 years of age in the monotherapy group.
There were no significant effects on the reduction in sitDBP due to gender, prior use of antihypertensives and baseline severity of hypertension. Owing to the small number of patients in the subgroups, the effects of race could not be assessed.
Tolerability results
Three hundred and nine patients who were randomised and received at least one dose of study medication were included in the tolerability assessment. The percentage of patients reporting at least one ontherapy AE was 39.5% (65/157) in the monotherapy group compared with 45.4% (69/152) in the combination group. However, in only 19 patients in the monotherapy group and in 25 patients in the combination group, the AEs were considered to be suspected or probably related to treatment ( Table 2) .
The majority of AEs were mild or moderate and the incidence of severe adverse events was low (1.3% for the monotherapy group and 2.6% for the combination group). The most common AE (irrespective of causality) in both groups was head- Table 2 Number (%) of on-therapy adverse events (AEs) considered by the investigator to be suspected or probably related to treatment reported by у1% of patients in either treatment group by preferred term ranked in descending order for eprosartan plus HCTZ ache, occurring in 4.5% and 5.3% of patients in the monotherapy and combination groups, respectively. The most common AEs recorded as suspected or probably related to study medication in the combination group were dizziness, insomnia and vertigo, which occurred more frequently than in the monotherapy group. By comparison, the most common AEs recorded as suspected or probably related in the eprosartan group were headache and anaemia, and the numbers were comparable with those seen in the combination group. The incidence of AEs was analysed by subgroup, with the frequency being generally lower for patients aged 65 years or over (33.3%) than for those patients aged less than 65 years (45.6%). However, meaningful comparisons of the AE profiles are difficult due to the differences in numbers of patients in each group (228 patients aged less than 65 years and 81 patients aged 65 years or over).
A total of seven patients experienced at least one non-fatal serious AE during the course of the study. Of these seven serious AEs, four occurred in the treatment period (three in the monotherapy group and one in the combination group), one occurred in the monotherapy run-in period, one occurred during the follow-up and one occurred during the screening period. The serious adverse event that occurred during the screening period was atrial fibrillation, and during the monotherapy run-in was myocardial infarction. These serious adverse events were considered to be unrelated to study medication. The serious adverse events in the monotherapy group during the treatment period were injury (unrelated to study medication), myocardial infarction (probably unrelated to study medication), and increased therapeutic response, which was probably related to study medication as the patient had taken a double-dose of eprosartan for 17 days. The serious adverse event in the combination group was neoplasm NOS (not otherwise specified), which was considered unrelated to study medication.
A total of 21 patients were withdrawn due to AEs occurring on-therapy during the entire study, with three patients being withdrawn due to a serious AE. The number of patients with AEs leading to withdrawal was similar for monotherapy (six patients) and combination therapy (five patients). The remaining 10 patients experienced adverse events leading to withdrawal during the monotherapy runin period.
There were no clinically significant changes in any laboratory parameters, vital signs or ECG parameters in either of the treatment groups.
Discussion
This study demonstrated that an OD combination product containing eprosartan 600 mg plus HCTZ 12.5 mg was more effective in lowering sitDBP than eprosartan 600 mg OD alone, when given to patients previously unresponsive to eprosartan monother-apy. The response rate was also higher when patients were given the combination product compared with eprosartan monotherapy. This study specifically set out to investigate a low-dose combination of eprosartan 600 mg plus HCTZ 12.5 mg vs eprosartan 600 mg only. Although the combination has previously been shown to be more effective than eprosartan alone, 14 this was in an open-label study, whereas the present study was a randomised, double-blind trial in non-responders to monotherapy.
These results are consistent with the findings of studies into the effects of other angiotensin II receptor blockers (valsartan, losartan) given in combination with HCTZ, which have also demonstrated a greater reduction in sitDBP and higher response rates when compared with the angiotensin receptor blocker alone. 12, 16 Long-term safety studies have shown that eprosartan 600 mg in combination with HCTZ 12.5 mg is the optimal combination for the reduction of blood pressure. 14, 15 Subgroup analyses showed that sitDBP was reduced to the same extent in patients aged less than 65 years compared with patients aged 65 years or over when given combination therapy. By contrast, in the monotherapy group, patients aged 65 years or over showed a much greater reduction in sitDBP compared with those aged less than 65 years. The baseline characteristics for vital signs were similar for both age groups and so do not explain why the older population had a more marked response to monotherapy compared with the younger population. There were no significant effects on reduction of sitDBP due to gender, prior use of antihypertensives or baseline severity of hypertension.
The tolerability profile for the combination therapy group was similar to that for the monotherapy group. Headache was the most frequent AE in both treatment groups and the majority of AEs were mild to moderate in intensity and not considered to be probably or suspected related to study treatment. Previous studies have shown that eprosartan has a placebo-like side-effect profile. 4, 5 The frequency of AEs leading to withdrawal was low and comparable between the two treatment groups. Out of 21 AEs leading to withdrawal, three were serious AEs and 14 were considered to be probably or suspected related to study medication. The most frequent AE leading to withdrawal appeared to be headache, but this only occurred in seven patients.
The most frequently observed AEs reported in patients taking combination therapy compared with monotherapy were dizziness, insomnia and vertigo. These AEs may be due to HCTZ as they have previously been observed in patients taking thiazide diuretics. 17 The most frequently reported AE of ACE inhibitors is cough, but in this study only 1.3% patients in the monotherapy group and 2% of patients in the combination group experienced coughing. This finding is in agreement with a longJournal of Human Hypertension term safety study which reported cough in less than 2.5% of patients. 14 Patients with essential hypertension are often asymptomatic and therefore unlikely to comply with treatment if it makes them feel worse. However, both eprosartan monotherapy and eprosartan in combination with HCTZ showed a low incidence of AEs, indicating that such treatment may improve the low levels of compliance often seen with other antihypertensive agents.
In this study of patients with essential hypertension who were unresponsive to eprosartan monotherapy for 3 weeks, a combination of eprosartan 600 mg and HCTZ 12.5 mg was shown to be an effective and well tolerated treatment. At study endpoint, there were statistically significant and clinically relevant reductions in sitDBP and sitSBP and an increase in response rates for the combination group compared with eprosartan therapy alone. This indicates that the combination therapy offers additional antihypertensive efficacy with no significant changes in the tolerability profile over eprosartan monotherapy. Previous studies have shown that compliance is increased with a reduced pill burden. 18 Thus, the availability of a combination of eprosartan plus HCTZ as a single tablet once-daily may have additional benefit of improved compliance.
